Pfizer Balance Sheet Health
Financial Health criteria checks 4/6
Pfizer has a total shareholder equity of $90.6B and total debt of $62.4B, which brings its debt-to-equity ratio to 68.8%. Its total assets and total liabilities are $208.0B and $117.4B respectively. Pfizer's EBIT is $16.4B making its interest coverage ratio 7.7. It has cash and short-term investments of $17.3B.
Key information
68.84%
Debt to equity ratio
US$62.40b
Debt
| Interest coverage ratio | 7.7x |
| Cash | US$17.32b |
| Equity | US$90.64b |
| Total liabilities | US$117.39b |
| Total assets | US$208.03b |
Recent financial health updates
Recent updates
Unlocking Pfizer's Value: Cost Controls And Oncology Pipeline
May 28Pfizer's Q1 Update May Mark A Bottom In The Stock
Apr 30Pfizer Earnings Preview: Pharma May Plumb New Depths After Obesity Drug Debacle
Apr 23It Looks Like Pfizer Inc.'s (NYSE:PFE) CEO May Expect Their Salary To Be Put Under The Microscope
Apr 17
Pfizer: Tasty 7% Yield
Apr 16
R&D And Savings Programs Will Strengthen Future Outlook
Focus on R&D productivity in 2025 may risk misalignment with market needs, impacting future revenue if new products underperform.Oncology Integration And Phase III Trials Will Redefine Future
Pfizer's oncology focus strengthens its portfolio and future revenue through Seagen integration and promising R&D pipeline developments in oncology and vaccines.Pfizer: Shares Stabilize At $25 As Institutions Begin To Load Up (Rating Upgrade)
Mar 28Pfizer: Bulls Need To Check Out Its Graham P/E
Mar 22Pfizer's Future Depends on Oncology Growth, New Products and operational efficiency
I think that Pfizer has a strong pipeline. The aquisition of seagen added many new oncology products that will continue to grow by 14% partially offseting the decline on sales of the covid-19 vaccinesPfizer: Undervalued Safe Haven In Risk-Off Market
Mar 11Pfizer Remains A Good Pick For Dividend Investors
Mar 04Market Still Lacking Some Conviction On Pfizer Inc. (NYSE:PFE)
Feb 28Why Pfizer's Stock Price Isn't Reflecting Its True Value
Feb 19Pfizer: 3 Key Risks That Warrant A Sell
Feb 12Pfizer Q4 Earnings: Solid Results, But Guidance And Patent Concerns Drive The Stock Down
Feb 04These 4 Measures Indicate That Pfizer (NYSE:PFE) Is Using Debt Extensively
Feb 04Pfizer Q4 Earnings Preview: 5 Critical Business Issues To Consider
Jan 28Pfizer's (NYSE:PFE) Upcoming Dividend Will Be Larger Than Last Year's
Jan 13Pfizer: My Top Play In 2025 Using Dogs Of The Dow Strategy
Jan 13Pfizer: One Of The Next Big AI Winners
Dec 30Pfizer (NYSE:PFE) Is Paying Out A Larger Dividend Than Last Year
Dec 30Pfizer: Time And Patience Ran Out (Rating Downgrade)
Dec 24Pfizer: I'm Short-Term Skeptical, Long-Term Positive Post 2025 Guidance Call
Dec 18Pfizer's (NYSE:PFE) Dividend Will Be Increased To $0.43
Dec 16Pfizer: Peer-Leading Dividend And Potential Substantial Shareholder Returns
Dec 11Pfizer: Too Cheap To Ignore
Dec 05Financial Position Analysis
Short Term Liabilities: PFE's short term assets ($45.9B) exceed its short term liabilities ($36.5B).
Long Term Liabilities: PFE's short term assets ($45.9B) do not cover its long term liabilities ($80.9B).
Debt to Equity History and Analysis
Debt Level: PFE's net debt to equity ratio (49.7%) is considered high.
Reducing Debt: PFE's debt to equity ratio has reduced from 78.2% to 68.8% over the past 5 years.
Debt Coverage: PFE's debt is well covered by operating cash flow (22.4%).
Interest Coverage: PFE's interest payments on its debt are well covered by EBIT (7.7x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/29 04:15 |
| End of Day Share Price | 2025/05/29 00:00 |
| Earnings | 2025/03/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Pfizer Inc. is covered by 54 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Kerry Holford | Berenberg |
| Luisa Hector | Berenberg |